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Hereditary neuropathywith liability to pressure palsies (HNPP) is an autosomal neuropathy that is commonly caused by a reciprocal
1.5Mb deletion on chromosome 17p11.2, at the site of the peripheral myelin protein 22 (PMP22) gene. Other patients with similar
phenotypes have been shown to harbor point mutations or small deletions, although there is some clinical variation across these
patients. In this report, we describe a case of HNPP with copy number changes in exon or promoter regions of PMP22. Multiplex
ligation-dependent probe analysis revealed an exon 1b deletion in the patient, who had been diagnosed with HNPP in the first
decade of life using molecular analysis.
1. Introduction
Hereditary neuropathy with liability to pressure palsies
(HNPP, OMIM number 162500) is an autosomal dominant
peripheral neuropathy characterized by recurrent peripheral
nerve palsies or sensory loss, often following minor trauma
or compression in various locations, including the brachial
plexus or common peroneal, ulnar, radial, or median nerves
[1]. Because the symptoms of HNPPmost commonly develop
in adolescence or adulthood, only a few cases of childhood-
onset HNPP have been reported [2, 3]. In children, other
conditions may also interfere with the diagnostic accuracy
of electrophysiological testing, and molecular genetic studies
are needed to confirm the disease. HNPP is caused by a
deletion of the peripheral myelin protein 22-kDa (PMP22,
OMIM number 601097) gene on chromosome 17p11.2, which
encodes an intrinsic, tetraspanmembrane glycoprotein that is
expressed mainly in Schwann cells and represents an impor-
tant, although minor, component of the compact myelin of
the peripheral nerves [4]. Charcot-Marie-Tooth neuropathy
type 1A (CMT1A) is alsomost often associated with a tandem
1.5Mb duplication of PMP22 [5]. PMP22 is a 40 kb gene that
consists of six exons, of which two alternatively transcribed
exons (1a and 1b) comprise the first exon of the gene [6, 7].
In this study, we report on a HNPP patient with rare copy
number changes detected by multiplex ligation-dependent
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probe analysis (MLPA) using improved set of probes for the
PMP22 gene.
2. Case Presentation
The patient was a 2-year-old boy admitted to the hospital
for the evaluation of left side weakness. He was born to
a 31-year-old Korean mother and a 28-year-old Indonesian
father at 36-week gestational age by cesarean section for
breech presentation. The brain CT showed small nodular
hemorrhages in the right cerebellar hemisphere; the brain
MRI revealed no evidence of abnormal findings and the
brain sonogram showed only mild flaring. EEG showed no
epileptiform discharge or evidence of abnormal slowing.
No retinopathy of prematurity was found. A conventional
chromosome study showed a normal karyotype. The nerve
conduction study revealed delays in conduction velocity as
measured by the compound motor action potential (CMAP)
in the right peroneal nerve. A screening test for 46 metabolic
disorders was negative. The dystrophia myotonica-protein
kinase gene PCR analysis for myotonic dystrophy I and
the MLPA for Duchenne muscular dystrophy and spinal
muscular atrophy were also negative.
Informed consent was obtained from the guardian of the
patient prior to the molecular analysis of the PMP22. There
were an additional 100 controls selected from individuals in
whom demyelinating disease was not clinically evident and
informed consent was also obtained before their enrollment
in the study. Genomic DNAwas extracted from EDTAwhole
blood samples with an Easy-DNA Kit (Invitrogen, Carlsbad,
CA, USA). MLPA was performed using the MLPA kit
(SALSAMLPAKIT P033 CMT1, MRCHolland, Amsterdam,
The Netherlands) according to the manufacturer’s instruc-
tions, as described in the protocol available online
(http://www.mlpa.com/WebForms/WebFormMain.aspx?Tag
= fNPBLedDVp38p-CxU2h0mQ..). MLPA fragment analy-
sis data were generated on the ABI 3500xl system (Applied
Biosystems) and analyzed using the GeneMarker software
(SoftGenetics, State College, PA, USA). To determine
whether the MLPA results were caused by the specific
mutations in the probe binding sites, PCR and direct
sequencing were performed using primers designed for all
exons and flanking introns of PMP22. To detect any sequence
variation, the sequences were compared to the reference
sequences using Sequencher software (Gene Codes, Ann
Arbor, MI, USA).
The MLPA analysis revealed a deletion of exons in the
patient. This finding was only present in the affected patient
and was not found in an analysis of 200 alleles from 100
subjects without evidence of neuromuscular disease. The
possibility of the presence of mutations in the probe binding
sites or in the region of deletion identified byMLPAwas ruled
out through direct sequencing; no mutation was identified.
3. Discussion
Some phenotypic variability has also been observed among
the CMT1A and HNPP patients, although the relationship
between genetic and phenotypic variation is unclear. The
patient, in whomHNPPwas identified during the first decade
of life, was revealed to have a novel deletion in the promoter
region (exon 1b) of PMP22. Since there have been only a small
number of HNPP cases reported during childhood, clinical
suspicion of the disease is often low and the symptoms may
be overlooked and detailed testing to definitively rule out
HNPP is often not performed [2, 3]. To further complicate
the diagnosis, the EMG in children is rather difficult to
perform, making genetic testing warranted only for patients
with possible HNPP. In our patient, the first and second EMG
results showed normal conduction, and only the third nerve
conduction test revealed a conduction delay in the peroneal
nerve suspicious of demyelinating peripheral neuropathy.
This final EMG result prompted us to further carry out
molecular studies to confirm the diagnosis. As mentioned in
Chromik et al. [8], genetic testing for patients with clinical
suspicion ofHNPP evenwhen nerve conduction study results
do not prefer HNPP could help physicians to diagnoseHNPP
in childhood. Future work will need to examine whether the
PMP22 gene dosage is regulated by the copy number change
in the promoter region as well.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgment
This work was supported by a research Grant from Yonsei
University Wonju College of Medicine (YUWCM-2012-17).
References
[1] O. Dubourg, P. Mouton, A. Brice, E. Leguern, and P. Bouche,
“Guidelines for diagnosis of hereditary neuropathywith liability
to pressure palsies,” Neuromuscular Disorders, vol. 10, no. 3, pp.
206–208, 2000.
[2] A. O. Bayrak, E. Battaloglu, H. Turker, I. Baris, and G. Oztas,
“Hereditary neuropathy with liability to pressure palsy (HNPP)
in childhood: a case study emphasizing the relevance of detailed
electrophysiological examination for suspected HNPP in the
first decade,” Brain andDevelopment, vol. 31, no. 6, pp. 445–448,
2009.
[3] K. Ichikawa and A. Nezu, “Hereditary neuropathy with liability
to pressure palsies in childhood: report of a case and a brief
review,” Brain & Development, vol. 27, no. 2, pp. 152–154, 2005.
[4] S. S. Scherer and L. Wrabetz, “Molecular mechanisms of
inherited demyelinating neuropathies,”GLIA, vol. 56, no. 14, pp.
1578–1589, 2008.
[5] P. F. Chance and K. H. Fischbeck, “Molecular genetics
of Charcot-Marie-Tooth disease and related neuropathies,”
Human Molecular Genetics, vol. 3, pp. 1503–1507, 1994.
[6] A. M. Jetten and U. Suteri, “The peripheral myelin protein 22
and epithelial membrane protein family,” Progress in Nucleic
Acid Research and Molecular Biology, vol. 64, pp. 97–129, 2000.
Case Reports in Genetics 3
[7] J. Li, B. Parker, C.Martyn, C.Natarajan, and J. Guo, “ThePMP22
gene and its related diseases,” Molecular Neurobiology, vol. 47,
no. 2, pp. 673–698, 2013.
[8] A. P. Chromik, E. S. Darol, B. R. Ryniewicz et al., “Clinical,
electrophysiological, and molecular findings in early onset
hereditary neuropathy with liability to pressure palsy,” Muscle
& Nerve, 2014.
